| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary targets of D-(-)-3-Phosphoglyceric acid disodium are the enzymes that utilize it as a substrate or are inhibited by it. It is a substrate for phosphoglycerate kinase in the glycolytic pathway. It also competitively inhibits yeast enolase. The compound is an intermediate in several biological pathways, most notably glycolysis/gluconeogenesis and the biosynthesis of serine, glycine, and threonine. By serving as a substrate or inhibitor, it helps in studying the function and regulation of these key metabolic enzymes.
|
|---|---|
| ln Vitro |
In vitro, D-(-)-3-Phosphoglyceric acid disodium is used as a substrate in enzymatic assays to measure the activity of phosphoglycerate kinase. The compound is also used to study the inhibition of yeast enolase. As an intermediate in glycolysis, it can be used to investigate metabolic flux and enzyme kinetics in cell-free systems. The compound is available with a purity of ≥93%.
|
| ln Vivo |
In vivo, D-(-)-3-Phosphoglyceric acid disodium is an intermediate in glycolysis and gluconeogenesis. It is involved in the biosynthesis of serine, glycine, and threonine. The compound plays a critical role in cellular energy metabolism and amino acid synthesis. However, it is not typically administered as a drug; rather, it is used as a research tool to study metabolic pathways.
|
| Enzyme Assay |
The in vitro enzyme assay for phosphoglycerate kinase involves incubating the enzyme with its substrates, 3-phosphoglycerate and ATP, in a suitable buffer system. The reaction produces 1,3-bisphosphoglycerate and ADP. The activity of phosphoglycerate kinase is measured by coupling the reaction to the oxidation of NADH, which is monitored spectrophotometrically at 340 nm. D-(-)-3-Phosphoglyceric acid disodium serves as the substrate for this assay. For enolase inhibition studies, the compound is incubated with the enzyme, and the conversion of 2-phosphoglycerate to phosphoenolpyruvate is measured.
|
| Cell Assay |
Cellular assays for D-(-)-3-Phosphoglyceric acid disodium typically involve the use of cell lines to study glycolysis and related metabolic pathways. Cells are cultured in medium containing the compound, and metabolic flux is analyzed using techniques such as mass spectrometry or NMR spectroscopy. The compound's effects on cellular energy metabolism, ATP production, and lactate production may be assessed. However, specific cellular assay protocols for this compound are not detailed in the available literature.
|
| Animal Protocol |
In vivo animal studies for D-(-)-3-Phosphoglyceric acid disodium would typically involve the administration of the compound to animal models to study its effects on glycolysis and metabolism. However, as a metabolic intermediate, it is not typically used as a drug. Instead, it is used as a research tool to study metabolic pathways. Specific in vivo study protocols for this compound are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
As a small molecule, the pharmacokinetic properties of D-(-)-3-Phosphoglyceric acid disodium would depend on its physicochemical characteristics. The compound is highly polar and negatively charged, which would limit its ability to cross cell membranes. It is likely to be rapidly metabolized and cleared from the circulation. Detailed ADME parameters such as half-life, bioavailability, and tissue distribution are not available in the public domain. The compound is typically stored under standard laboratory conditions.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for D-(-)-3-Phosphoglyceric acid disodium in the available literature. As a research chemical, it is generally considered safe at research doses. Standard safety precautions should be followed when handling the compound. Toxicity studies would be required if the compound were to be developed further for therapeutic applications. The compound is supplied with a purity of >99.99%.
|
| References |
|
| Additional Infomation |
D-(-)-3-Phosphoglyceric acid disodium (3-Phospho-D-glyceric acid disodium) is a pivotal component within the biomedical sector, acting as a fundamental substrate for enzymatic assays. It is a phosphorylated glyceric acid compound and an intermediate in glycolysis. The compound has a molecular formula of C3H5Na2O7P and a molecular weight of 230.02. It is an intermediate in glycolysis/gluconeogenesis and the biosynthesis of serine, glycine, and threonine. It competitively inhibits yeast enolase. The compound is used to gauge the performance of phosphoglycerate kinase and associated inhibitors.
|
| Molecular Formula |
C3H5NA2O7P
|
|---|---|
| Molecular Weight |
230.02
|
| Exact Mass |
229.957
|
| CAS # |
80731-10-8
|
| PubChem CID |
16219906
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
174
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@H](C(=O)[O-])O)OP(=O)(O)[O-].[Na+].[Na+]
|
| InChi Key |
RGCJWQYUZHTJBE-YBBRRFGFSA-L
|
| InChi Code |
InChI=1S/C3H7O7P.2Na/c4-2(3(5)6)1-10-11(7,8)9;;/h2,4H,1H2,(H,5,6)(H2,7,8,9);;/q;2*+1/p-2/t2-;;/m1../s1
|
| Chemical Name |
disodium;(2R)-2-hydroxy-3-[hydroxy(oxido)phosphoryl]oxypropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (434.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3474 mL | 21.7372 mL | 43.4745 mL | |
| 5 mM | 0.8695 mL | 4.3474 mL | 8.6949 mL | |
| 10 mM | 0.4347 mL | 2.1737 mL | 4.3474 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
